Literature DB >> 20738338

The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36.

W J Neary1, V F Hillier, T Flute, S D G Stephens, R T Ramsden, D G R Evans.   

Abstract

OBJECTIVES: To investigate the relationship between those issues concerning quality of life in patients with neurofibromatosis type 2 (NF2) as identified by the closed set NF2 questionnaire and the eight norm-based measures and the physical component summary (PCS) and mental component summary (MCS) scores of the Short Form-36 (SF-36) Questionnaire.
DESIGN: Postal questionnaire study.
SETTING: Questionnaires sent to subjects' home addresses. PARTICIPANTS: Eighty-seven adult subjects under the care of the Manchester Multidisciplinary NF2 Clinic were invited to participate. MAIN OUTCOME MEASURES: Sixty-two (71%) completed sets of closed set NF2 questionnaires and SF-36 questionnaires were returned.
RESULTS: Subjects with NF2 scored less than the norm of 50 on both the physical component summary and mental component summary scores and the eight individual norm-based measures of the Short Form-36 questionnaire. Correlations (using Kendall's tau) were examined between patients' perceptions of their severity of difficulty with the following activities and the eight norm-based measures and the physical component summary and mental component summary scores of the Short Form-36 questionnaire: Communicating with spouse/significant other (N = 61). The correlation coefficients were significant at the 0.01 level for the mental component summary score, together with three of the norm-based scores [vitality (VT), social functioning and role emotional]. Social communication (N = 62). All 10 correlations were significant at the 0.01 or 0.001 level. Balance (N = 59). All 10 correlations were highly significant at the P < 0.001 level. Hearing difficulties (N = 61). All correlations were significant at either the 0.01 level or less apart from the mental component summary score and three of the norm-based scores (role physical, VT and mental health). Mood change (N = 61). All correlations were significant at the 0.01 level or less, apart from one norm-based score (role physical).
CONCLUSIONS: The Short Form-36 questionnaire has allowed us to relate patients' perceptions of their difficulties, as identified by the closed set NF2 questionnaire, to the physical and mental domains measured by this validated and widely used scale, and has provided further insight into areas of functioning affected by NF2.

Entities:  

Mesh:

Year:  2010        PMID: 20738338     DOI: 10.1111/j.1749-4486.2010.02176.x

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  11 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

2.  First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial.

Authors:  Christopher J Funes; Ryan A Mace; Erik A Macklin; Scott R Plotkin; Justin T Jordan; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2019-05-02       Impact factor: 4.130

3.  The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2.

Authors:  Rachael E Hornigold; John F Golding; Guy Leschziner; Rupert Obholzer; Michael J Gleeson; Nick Thomas; Daniel Walsh; Shakeel Saeed; Rosalie E Ferner
Journal:  J Neurol Surg B Skull Base       Date:  2012-04

4.  Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Authors:  Matthieu Peyre; Stephane Goutagny; Sandrine Imbeaud; Alexis Bozorg-Grayeli; Michele Felce; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2011-07-28       Impact factor: 12.300

Review 5.  Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.

Authors:  Ana-Maria Vranceanu; Vanessa L Merker; Elyse Park; Scott R Plotkin
Journal:  J Neurooncol       Date:  2013-07-02       Impact factor: 4.130

6.  Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live‑video randomized control trial.

Authors:  Jonathan Greenberg; Sarah Carter; Ethan Lester; Christopher J Funes; Eric A Macklin; Scott Plotkin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2019-11-01       Impact factor: 4.130

7.  Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.

Authors:  Scott R Plotkin; Simone L Ardern-Holmes; Fred G Barker; Jaishri O Blakeley; D Gareth Evans; Rosalie E Ferner; Tessa A Hadlock; Chris Halpin
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

8.  Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.

Authors:  Rosalie E Ferner; Adam Shaw; D Gareth Evans; Dympna McAleer; Dorothy Halliday; Allyson Parry; F Lucy Raymond; Juliette Durie-Gair; C Oliver Hanemann; Rachel Hornigold; Patrick Axon; John F Golding
Journal:  J Neurol       Date:  2014-03-12       Impact factor: 4.849

9.  Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome.

Authors:  Daphne L Wang; Kelly B Smith; Sonia Esparza; Fawn A Leigh; Alona Muzikansky; Elyse R Park; Scott R Plotkin
Journal:  Genet Med       Date:  2012-08-09       Impact factor: 8.822

10.  Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials.

Authors:  Heather L Thompson; Ann Blanton; Barbara Franklin; Vanessa L Merker; Kevin H Franck; D Bradley Welling
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.